# US 5,705,606 A · Peptides derived from GPIIIa

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,705,606 A
- Document ID: US5705606A
- Status: Granted
- Kind: A
- Application number: 08/170,596
- Filed: 1993-12-21
- Granted: 1998-01-06
- Earliest claimed: 1988-06-30
- Assignees: COR Therapeutics, Inc.
- Inventors: Israel F. Charo; Laurence A. Fitzgerald; David R. Phillips
- Web page: https://patentgrep.com/patent/US5705606A

## CPC

- C07K 14/70557: {Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- Y10S 530/806: Antigenic peptides or proteins
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention provides oligopeptides corresponding to regions of the GPIIIa protein, which are capable of specifically binding aggregation mediators, such as fibrinogen. The oligopeptides will typically comprise at least about 5 to 20 amino acids, and are thus non-immunogenic and easy to produce, formulate and administer.

## Claims

### Claim 1

An isolated and purified oligopeptide comprising the amino acid sequence:
Glu-Glu-Val-Lys-Lys-Gln-Ser-Val-Ser-Arg-Asn-Arg-Asp-Ala-Pro-Glu-Gly-Gly-Phe -Asp (SEQ ID NO.:9);
Asn-Glu-Glu-Val-Lys-Lys-Gln-Ser-Val-Ser-Arg-Asn-Arg-Asp-Ala-Pro-Glu-Gly-Gly -Phe-Asp-Ala-Ile-Met-Gln-Ala (SEQ ID NO.:11);
Asn-Glu-Glu-Val-Lys-Lys-Gln-Ser-Val-Ser-Arg-Asn-Arg-Asp-Ala-Pro-Glu-Gly-Gly (SEQ ID NO.:12);
Ser-Val-Ser-Arg-Asn-Arg-Asp-Ala-Pro-Glu-Gly-Gly-Phe-Asp-Ala-Ile-Met-Gln-Ala (SEQ ID NO.:13); or
Ser-Val-Ser-Arg-Asn-Arg-Asp-Ala-Pro-Glu-Gly-Gly; (SEQ ID NO.:14)
wherein the oligopeptide has less than about 50 continuous amino acids from the naturally occurring GPIIIa sequence.

### Claim 2 (depends on 1)

The oligopeptide according to claim 1, wherein the oligopeptide is a salt.

### Claim 3 (depends on 1)

The oligopeptide according to claim 1, wherein the carboxy-terminal amino acid of the oligopeptide is free or amidated.

### Claim 4 (depends on 1)

The oligopeptide according to claim 1, wherein the amino-terminal amino acid of the oligopeptide is free or acetylated.

### Claim 5 (depends on 1)

The oligopeptide according to claim 1, wherein the oligopeptide is conjugated to a carrier, and wherein the conjugate has less than about 50 continuous amino acids from the naturally occurring GPIIIa sequence.

### Claim 6 (depends on 5)

The oligopeptide according to claim 5, wherein the carrier is a protein.